A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

NCT05366478 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Non Small Cell Lung Cancer
Cervical Carcinoma

Interventions

DRUG: Autologous tumor infiltrating lymphocytes (TILs)

Sponsor

Suzhou BlueHorse Therapeutics Co., Ltd.